Skip to main content
FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO, Oncology
Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma
Read More
FDA Approvals, Lymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
Read More
FDA Approvals, Lymphoma
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
Read More
Lymphoma
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
Chase Doyle
Chase Doyle
Read More
Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
Chase Doyle
Chase Doyle
Read More
FDA Approvals, Lymphoma
Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients
Read More
Leukemia, Lymphoma, Oncology
Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Chase Doyle
Chase Doyle
Read More
Leukemia, Lymphoma, Oncology
Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular and Marginal-Zone Lymphoma
Wayne Kuznar
Wayne Kuznar
Read More
Leukemia, Lymphoma, Oncology
CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma
Chase Doyle
Chase Doyle
Read More
Lymphoma
Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma
Chase Doyle
Chase Doyle
Read More
Page 1 of 3
Results 1 - 10 of 29